Cargando…
Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study
BACKGROUND: Information about the timing involved in various stages of making new drugs available to Canadians is important for understanding how a national pharmacare plan will affect timely access to new drugs. I explored the timing of the various steps between receiving a Notice of Compliance and...
Autor principal: | Lexchin, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671297/ https://www.ncbi.nlm.nih.gov/pubmed/36379586 http://dx.doi.org/10.9778/cmajo.20220063 |
Ejemplares similares
-
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis
por: Lexchin, Joel
Publicado: (2017) -
New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis
por: Lexchin, Joel
Publicado: (2023) -
Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study
por: Lexchin, Joel
Publicado: (2022) -
Does Variation among Provincial Drug Formulary Antimicrobial Listings in Canada Influence Prescribing Rates?
por: Glass-Kaastra, Shiona K., et al.
Publicado: (2014) -
Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study
por: Lexchin, Joel
Publicado: (2023)